Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

166.29 

-3.26 -1.9%

as of Nov 15 '18

52 Week Range:

134.40 180.40


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 10.57
13.42
16.01
18.80
22.86
19.87
20.94
27.40
33.95
39.43
37.38
growth rate 27.0% 19.3% 17.4% 21.6% -13.1% 5.4% 30.9% 23.9% 16.1% -5.2%
Earnings BIT 3,122.06
4,139.10
4,099.68
4,194.29
3,271.86
3,949.88
4,154.87
6,765.00
8,629.00
9,832.00
10,418.00
growth rate 32.6% -1.0% 2.3% -22.0% 20.7% 5.2% 62.8% 27.6% 13.9% 6.0%
Avg.PE 16.84
14.90
12.56
11.60
13.40
15.58
17.24
20.56
14.93
14.83
55.13
growth rate -11.5% -15.7% -7.6% 15.5% 16.3% 10.7% 19.3% -27.4% -0.7% 271.8%
ROA 9.25
11.81
12.11
11.13
7.98
8.42
8.44
7.63
9.87
10.35
2.51
growth rate 27.7% 2.5% -8.1% -28.3% 5.5% 0.2% -9.6% 29.4% 4.9% -75.8%
ROE 17.19
21.94
21.39
19.85
17.14
22.82
24.69
21.55
25.77
26.65
7.18
growth rate 27.6% -2.5% -7.2% -13.7% 33.1% 8.2% -12.7% 19.6% 3.4% -73.1%
ROIC 11.16
14.08
15.51
13.21
9.84
11.24
11.35
10.33
12.69
13.30
3.29
growth rate 26.2% 10.2% -14.8% -25.5% 14.2% 1.0% -9.0% 22.9% 4.8% -75.3%
Cur. Ratio 2.11
3.12
4.89
3.52
4.80
3.81
3.44
4.95
4.44
4.11
5.49
growth rate 47.9% 56.7% -28.0% 36.4% -20.6% -9.7% 43.9% -10.3% -7.4% 33.6%
Quick Ratio 1.50
2.38
4.02
3.01
4.09
3.24
2.78
4.22
3.97
3.68
4.98
growth rate 58.7% 68.9% -25.1% 35.9% -20.8% -14.2% 51.8% -5.9% -7.3% 35.3%
Leverage 1.94
1.79
1.75
1.82
2.57
2.85
2.99
2.68
2.55
2.60
3.17
growth rate -7.7% -2.2% 4.0% 41.2% 10.9% 4.9% -10.4% -4.9% 2.0% 21.9%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 1,507.69
1,662.74
1,840.91
2,283.21
1,985.19
2,126.31
2,546.00
2,995.00
3,165.00
3,237.00
growth rate 10.3% 10.7% 24.0% -13.1% 7.1% 19.7% 17.6% 5.7% 2.3%
Acct.Payable 995.00
965.00
917.00
1,352.00
growth rate -3.0% -5.0% 47.4%
Cur.Assets 11,070.23
14,925.99
18,234.90
21,754.32
24,605.18
21,576.14
34,713.00
38,515.00
46,010.00
49,476.00
growth rate 34.8% 22.2% 19.3% 13.1% -12.3% 60.9% 11.0% 19.5% 7.5%
Total Assets 26,504.99
31,243.50
34,284.36
38,529.90
42,808.54
52,132.95
69,009.00
71,449.00
77,626.00
79,954.00
growth rate 17.9% 9.7% 12.4% 11.1% 21.8% 32.4% 3.5% 8.7% 3.0%
Cash 1,290.23
2,273.75
2,591.47
5,476.23
2,567.82
2,999.86
3,731.00
4,144.00
3,241.00
3,800.00
growth rate 76.2% 14.0% 111.3% -53.1% 16.8% 24.4% 11.1% -21.8% 17.3%
Inventory 1,509.15
1,750.25
1,594.14
1,958.39
2,163.37
2,380.18
2,647.00
2,435.00
2,745.00
2,834.00
growth rate 16.0% -8.9% 22.9% 10.5% 10.0% 11.2% -8.0% 12.7% 3.2%
Cur.Liabilities 3,553.59
3,053.47
5,179.79
4,536.45
6,457.78
6,265.41
7,008.00
8,664.00
11,204.00
9,020.00
growth rate -14.1% 69.6% -12.4% 42.4% -3.0% 11.9% 23.6% 29.3% -19.5%
Liabilities 11,678.26
13,372.84
15,406.91
23,527.43
27,781.64
34,712.46
43,231.00
43,366.00
47,751.00
54,713.00
growth rate 14.5% 15.2% 52.7% 18.1% 25.0% 24.5% 0.3% 10.1% 14.6%
LT Debt 7,160.00
6,673.70
8,357.83
8,573.06
16,827.61
18,948.41
23,354.77
30,215.00
29,182.00
30,193.00
34,190.00
growth rate -6.8% 25.2% 2.6% 96.3% 12.6% 23.3% 29.4% -3.4% 3.5% 13.2%
Equity 17,869.00
14,826.74
17,870.66
18,877.45
15,002.46
15,026.90
17,420.49
25,778.00
28,083.00
29,875.00
25,241.00
growth rate -17.0% 20.5% 5.6% -20.5% 0.2% 15.9% 48.0% 8.9% 6.4% -15.5%
Common Shares 1,123.00
1,075.00
1,021.00
965.00
912.00
787.00
765.00
770.00
766.00
754.00
735.00
growth rate -4.3% -5.0% -5.5% -5.5% -13.7% -2.8% 0.7% -0.5% -1.6% -2.5%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 1,267.00
488.75
417.85
457.27
447.02
543.21
546.36
718.00
594.00
738.00
664.00
growth rate -61.4% -14.5% 9.4% -2.2% 21.5% 0.6% 31.4% -17.3% 24.2% -10.0%
Cash Dividends 0.00
0.00
0.00
0.00
394.20
881.43
1,115.59
1,851.00
2,396.00
2,998.00
3,365.00
growth rate 123.6% 26.6% 65.9% 29.4% 25.1% 12.2%
Cash From OA 5,401.00
4,355.07
4,995.30
4,562.47
4,035.82
4,637.37
4,959.82
8,952.00
9,731.00
10,354.00
11,177.00
growth rate -19.4% 14.7% -8.7% -11.5% 14.9% 7.0% 80.5% 8.7% 6.4% 8.0%
FCF per Share 2.20
3.53
3.60
3.90
4.15
5.56
4.33
7.58
10.34
9.84
11.82
growth rate 60.5% 2.0% 8.3% 6.4% 34.0% -22.1% 75.1% 36.4% -4.8% 20.1%
Sale Purchase of Stock 186.00
-1,867.00
-2,965.00
-3,160.00
growth rate -100.0% 0.0% 0.0%
FCF 4,134.00
5,316.00
5,806.00
5,207.00
4,552.00
5,193.00
5,598.00
7,552.00
8,428.00
9,517.00
10,513.00
growth rate 28.6% 9.2% -10.3% -12.6% 14.1% 7.8% 34.9% 11.6% 12.9% 10.5%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 11,530.00
10,911.68
11,543.75
11,867.79
12,284.85
13,611.73
14,724.16
20,063.00
21,662.00
22,991.00
22,849.00
growth rate -5.4% 5.8% 2.8% 3.5% 10.8% 8.2% 36.3% 8.0% 6.1% -0.6%
Op.Income 3,792.14
4,340.93
4,371.68
3,399.58
4,396.91
4,625.54
6,765.00
8,629.00
9,832.00
10,418.00
growth rate 14.5% 0.7% -22.2% 29.3% 5.2% 46.3% 27.6% 13.9% 6.0%
IBT 3,647.41
4,102.83
4,191.92
3,271.86
3,949.10
4,150.93
5,585.00
7,978.00
9,163.00
9,597.00
growth rate 12.5% 2.2% -22.0% 20.7% 5.1% 34.6% 42.9% 14.9% 4.7%
Net Income 2,947.02
3,630.58
3,647.93
2,903.68
3,425.60
4,005.86
5,158.00
6,939.00
7,722.00
1,979.00
growth rate 23.2% 0.5% -20.4% 18.0% 16.9% 28.8% 34.5% 11.3% -74.4%
EPS 2.82
3.77
4.51
4.79
4.04
5.52
6.64
6.70
9.06
10.24
2.69
growth rate 33.7% 19.6% 6.2% -15.7% 36.6% 20.3% 0.9% 35.2% 13.0% -73.7%
Gross Profit 11,763.00
9,241.80
9,895.21
10,117.54
10,371.40
11,089.63
12,086.17
15,745.00
17,487.00
18,829.00
18,926.00
growth rate -21.4% 7.1% 2.3% 2.5% 6.9% 9.0% 30.3% 11.1% 7.7% 0.5%
R&D 2,203.72
2,257.98
2,281.63
2,496.86
2,664.79
3,219.04
4,248.00
4,006.00
3,840.00
3,562.00
growth rate 2.5% 1.1% 9.4% 6.7% 20.8% 32.0% -5.7% -4.1% -7.2%

Quarterly Statements

Item Name Jun '17 Sep '17 Dec '17 Mar '18 Jun '18
Earnings BIT 2,696.00
2,725.00
2,801.00
2,722.00
2,794.00
growth rate 1.1% 2.8% -2.8% 2.7%
Balance Sheet Jun '17 Sep '17 Dec '17 Mar '18 Jun '18
Acct.Receivable 3,560.00
3,404.00
3,237.00
3,633.00
3,504.00
growth rate -4.4% -4.9% 12.2% -3.6%
Acct.Payable 883.00
879.00
1,352.00
1,089.00
1,026.00
growth rate -0.5% 53.8% -19.5% -5.8%
Cur.Assets 48,442.00
49,752.00
49,476.00
40,689.00
37,970.00
growth rate 2.7% -0.6% -17.8% -6.7%
Total Assets 79,587.00
80,331.00
79,954.00
71,164.00
67,684.00
growth rate 0.9% -0.5% -11.0% -4.9%
Cash 2,629.00
3,000.00
3,800.00
9,741.00
10,131.00
growth rate 14.1% 26.7% 156.3% 4.0%
Inventory 2,961.00
2,927.00
2,834.00
2,952.00
3,063.00
growth rate -1.2% -3.2% 4.2% 3.8%
Cur.Liabilities 7,815.00
8,193.00
9,020.00
10,479.00
11,205.00
growth rate 4.8% 10.1% 16.2% 6.9%
Liabilities 47,865.00
48,102.00
54,713.00
55,544.00
52,775.00
growth rate 0.5% 13.7% 1.5% -5.0%
LT Debt 33,603.00
33,777.00
34,190.00
33,358.00
30,209.00
growth rate 0.5% 1.2% -2.4% -9.4%
Equity 31,722.00
32,229.00
25,241.00
15,620.00
14,909.00
growth rate 1.6% -21.7% -38.1% -4.6%
Common Shares 30,793.00
30,898.00
30,992.00
31,001.00
31,048.00
growth rate 0.3% 0.3% 0.0% 0.2%
Cash Flow Statement Jun '17 Sep '17 Dec '17 Mar '18 Jun '18
Capital Expenditures 185.00
158.00
153.00
155.00
187.00
growth rate -14.6% -3.2% 1.3% 20.7%
Cash Dividends 846.00
838.00
834.00
951.00
865.00
growth rate -1.0% -0.5% 14.0% -9.0%
Cash From OA 2,326.00
3,454.00
3,012.00
2,727.00
2,102.00
growth rate 48.5% -12.8% -9.5% -22.9%
Sale Purchase of Stock -976.00
-809.00
-789.00
-10,697.00
growth rate 0.0% 0.0% 0.0%
FCF 2,141.00
3,296.00
2,859.00
2,572.00
1,915.00
growth rate 54.0% -13.3% -10.0% -25.5%
Income Statement Jun '17 Sep '17 Dec '17 Mar '18 Jun '18
Sales 5,810.00
5,773.00
5,802.00
5,554.00
6,059.00
growth rate -0.6% 0.5% -4.3% 9.1%
Op.Income 2,696.00
2,725.00
2,801.00
2,722.00
2,794.00
growth rate 1.1% 2.8% -2.8% 2.7%
IBT 2,542.00
2,381.00
2,214.00
2,619.00
2,647.00
growth rate -6.3% -7.0% 18.3% 1.1%
Net Income 2,151.00
2,021.00
-4,264.00
2,311.00
2,296.00
growth rate -6.0% -100.0% 100.0% -0.7%
EPS
growth rate
Gross Profit 4,786.00
4,783.00
4,889.00
4,610.00
5,035.00
growth rate -0.1% 2.2% -5.7% 9.2%
R&D 873.00
877.00
1,043.00
760.00
869.00
growth rate 0.5% 18.9% -27.1% 14.3%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (38.76)

YOY Growth Grade:

D (48.26)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 52.85 51.84 15.75
EPS / Growth 3.21

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 2.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 2.7% 2.7% 2.7%
Future PE 5.32 10.54 10.54
Future EPS 4.17 4.17 4.17
Value Price
MOS %
5.49
-96.7%
10.86
-93.5%
10.86
-93.5%
MOS Price 2.74 5.43 5.43
IRT 32.43 32.43 32.43

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.